Publications by authors named "Giulio Muscedere"
This prospective single-center study enrolled 50 women with 51 contrast-enhanced mammography (CEM)-enhancing lesions that lacked a sonographic or mammographic correlate. Trial participants underwent CEM-guided biopsy. Biopsy was technically successful for 46 lesions and was not performed for five nonvisualized lesions (all nonmass enhancement), yielding a cancellation rate of 9.
View Article and Find Full Text PDFIntroduction: Cytomegalovirus (CMV) is a common intrauterine infection and the developing nervous system is a frequent target, suffering a range of injuries from subclinical to catastrophic.
Case Presentation: A 20-week gestational age fetus was found to have a large echogenic focus in one cerebral hemisphere. Congenital CMV infection was identified by amniocentesis and maternal serology.
Article Synopsis
- The study looked at how much tumors move during radiation treatment for early-stage breast cancer patients and whether a 5 mm safety margin is enough to make sure the radiation hits the right spot.!* -
- Researchers used special markers and imaging to track tumor movements in 61 patients, finding that most of the time, the movement was less than 5 mm, but some patients did move more than that.!* -
- The conclusion was that a 5 mm margin is okay for how tumors move up and down or forward and back, but for side-to-side movement, they might need a larger margin or better ways to keep patients still during treatment.!*
Purpose: To determine the effect of dose fractionation and time delay post-neoadjuvant stereotactic ablative radiotherapy (SABR) on dynamic contrast-enhanced (DCE)-MRI parameters in early stage breast cancer patients.
Materials And Methods: DCE-MRI was acquired in 17 patients pre- and post-SABR. Five patients were imaged 6-7 days post-21 Gy/1fraction (group 1), six 16-19 days post-21 Gy/1fraction (group 2), and six 16-18 days post-30 Gy/3 fractions every other day (group 3).
Concurrent Neoadjuvant Chemotherapy and Radiation Therapy in Locally Advanced Breast Cancer.
Int J Radiat Oncol Biol Phys
November 2017
Purpose: To evaluate whether concurrent neoadjuvant radiation added to standard chemotherapy could increase the pathologic complete response (pCR) to treatment for locally advanced breast cancer (LABC).
Methods And Materials: This prospective phase 2 trial recruited 32 LABC patients from 2009 to 2011. Patients received neoadjuvant every-3-weekly 5-fluorouracil (500 mg/m), epirubicin (100 mg/m), and cyclophosphamide (500 mg/m) for 3 cycles, followed by weekly docetaxel (35 mg/m) for 9 cycles.